Kidney cancer PDOXs reveal patient‐specific pro‐malignant effects of antiangiogenics and its molecular traits-Reference-Cited by-同舟云学术

Kidney cancer PDOXs reveal patient‐specific pro‐malignant effects of antiangiogenics and its molecular traits

Published:2020-11-05 Issue:12 Volume:12 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Moserle Lidia¹,Pons Roser¹,Martínez‐Lozano Mar¹,Jiménez‐Valerio Gabriela A¹,Vidal August²,Suárez Cristina³,Trilla Enrique⁴,Jiménez José³,Torres Inés⁵,Carles Joan³,Senserrich Jordi¹,Aguilar Susana¹,Palomero Luis⁶,Amadori Alberto⁷⁸,Casanovas Oriol¹^ORCID

Affiliation:

1. Tumor Angiogenesis Group ProCURE Program Catalan Institute of Oncology, OncoBell Program, IDIBELL Barcelona Spain

2. Department of Pathology University Hospital of Bellvitge Bellvitge Biomedical Research Institute (IDIBELL) CIBERONC Barcelona Spain

3. Medical Oncology Department Vall d’Hebron Hospital Barcelona Spain

4. Surgery Department Vall d’Hebron Hospital Barcelona Spain

5. Pathology Department Vall d’Hebron Hospital Barcelona Spain

6. ProCURE Program Catalan Institute of Oncology. OncoBell Program, IDIBELL Barcelona Spain

7. Department of Surgery, Oncology and Gastroenterology University of Padova Padova Italy

8. Veneto Institute of Oncology IOV – IRCCS Padua Italy

Funder

Ministerio de Economía, Industria y Competitividad, Gobierno de España

Associazione Italiana per la Ricerca sul Cancro